Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, SAD and MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-3403 in Healthy Volunteers and Subjects With Elevated LDL-C
NCT06239714 is registered in ClinicalTrials.gov with Suzhou Sanegene Bio Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled, SAD and MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-3403 in Healthy Volunteers and Subjects With Elevated LDL-C
- Lead sponsor
- Suzhou Sanegene Bio Inc.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- February 18, 2024
- Completion date
- May 30, 2025
- Enrollment
- 64 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.